This brand name is authorized in Austria, Spain, France
The drug DOPAVIEW contains one active pharmaceutical ingredient (API):
|
1
Fluorodopa ¹⁸F
UNII 2C598205QX - FLUORODOPA F-18
|
|
Fluorodopa F18 is a radioactive diagnostic agent used in PET imaging. In dopaminergic nerve terminals in the brain, fluorodopa (FDOPA) F18 is decarboxylated by amino acid decarboxylase to fluorodopamine (FDA) F18 and stored in presynaptic vesicles in the brain. The accumulation of F18 FDA in the striatum is visually detected in the PET scan. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| V09IX05 | Fluorodopa (18F) | V Various → V09 Diagnostic radiopharmaceuticals → V09I Tumour detection → V09IX Other diagnostic radiopharmaceuticals for tumour detection |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: ES | Centro de información online de medicamentos de la AEMPS | Identifier(s): 83007 |
| Country: FR | Base de données publique des médicaments | Identifier(s): 63099647 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
